By Fineline Cube 
Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China to initiate a real-world study in the Bo’ao Lecheng International Medical Tourism Pilot Zone for its OT-703 (ILUVIEN®, fluocinonide intravitreal implant).
Partnership and Rights Acquisition
Ocumension secured development and commercialization rights to fluocinonide from US-based Alimera Sciences through an agreement signed in April 2021. The deal encompasses Greater China, South Korea, and Southeast Asia.
Product Overview
In the US, fluocinonide is marketed under the trade name Iluvien and is the only sustained-release corticosteroid intraocular implant approved for diabetic macular edema (DME). It is designed to provide sustained effects for up to three years.-Fineline Info & Tech